Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (71-80 of 186) with videos related to

Pageof 19
Sort By:
BMC Cancer|November 23, 2014
Oxidative stress in susceptibility to breast cancer: study in Spanish populationPatricia Rodrigues, Griselda de Marco, Jessica Furriol, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma riskMarta J Llorca-Cardeñosa, Maria Peña-Chilet, Matias Mayor, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 18, 2008
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007Juan de la Haba-Rodríguez, Emilio Alba, Agustí Barnadas, et al.
Clinical Breast Cancer|November 21, 2007
The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trialsIgnasi Tusquets, Laura G Estévez, Isabel Alvarez, et al.
Cancers|September 28, 2023
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER TherapiesMarta Tapia, Cristina Hernando, María Teresa Martínez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2022
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysisJuan Carlos Vazquez, Silvia Antolin, Manuel Ruiz-Borrego, et al.
Scientific Reports|March 31, 2019
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factorsEduardo Tormo, Sandra Ballester, Anna Adam-Artigues, et al.
Medicina Oral, Patologia Oral Y Cirugia Bucal|August 1, 2007
Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonatesJosé Bagán, Juan Blade, Jose Manuel Cozar, et al.
Breast Cancer Research and Treatment|July 14, 2011
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Milvia Zambetti, Mauro Mansutti, Patricia Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Progress against solid tumors in danger: the metastatic breast cancer exampleJavier Cortés, Emiliano Calvo, Antonio González-Martín, et al.
Pageof 19

Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
BMC Cancer|November 23, 2014
Oxidative stress in susceptibility to breast cancer: study in Spanish populationPatricia Rodrigues, Griselda de Marco, Jessica Furriol, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma riskMarta J Llorca-Cardeñosa, Maria Peña-Chilet, Matias Mayor, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 18, 2008
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007Juan de la Haba-Rodríguez, Emilio Alba, Agustí Barnadas, et al.
Clinical Breast Cancer|November 21, 2007
The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trialsIgnasi Tusquets, Laura G Estévez, Isabel Alvarez, et al.
Cancers|September 28, 2023
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER TherapiesMarta Tapia, Cristina Hernando, María Teresa Martínez, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2022
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysisJuan Carlos Vazquez, Silvia Antolin, Manuel Ruiz-Borrego, et al.
Scientific Reports|March 31, 2019
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factorsEduardo Tormo, Sandra Ballester, Anna Adam-Artigues, et al.
Medicina Oral, Patologia Oral Y Cirugia Bucal|August 1, 2007
Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonatesJosé Bagán, Juan Blade, Jose Manuel Cozar, et al.
Breast Cancer Research and Treatment|July 14, 2011
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Milvia Zambetti, Mauro Mansutti, Patricia Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2012
Progress against solid tumors in danger: the metastatic breast cancer exampleJavier Cortés, Emiliano Calvo, Antonio González-Martín, et al.
Pageof 19